The Mapmygenome acquisition of Canadian personal genomics company dnaPower Inc. was completed by October 21, 2026, expanding the buyer’s North American presence. The transaction brings together two businesses focused on personal genomics, with management describing a centralized platform for several types of testing.
Key Takeaways
- Mapmygenome has completed its purchase of dnaPower, rather than merely agreeing to a proposed deal.
- The company has not disclosed the transaction value.
- Management says the combination brings DNA, microbiome, pharmacogenetic and longevity testing together in North America.
Table of Contents
- Mapmygenome acquisition expands regional testing presence
- Gut microbiome testing is an existing product area
- Conclusion
Mapmygenome acquisition expands regional testing presence
Mapmygenome founder and chief executive Anu Acharya said combining dnaPower with Mapmygenome’s global presence creates a centralized North American platform for DNA, microbiome, pharmacogenetic and longevity testing services.
The company also described AI-driven multi-omics testing as part of the combined platform’s scope. The announced rationale centers on geographic reach and testing capabilities; the disclosure did not quantify expected revenue benefits or cost savings.
| Item | Details |
|---|---|
| Acquirer headquarters | Hyderabad, India |
| Acquired company headquarters | Vancouver, Canada |
| Transaction value | Not disclosed |
Gut microbiome testing is an existing product area
Gut microbiome testing is already part of Mapmygenome’s offering. Its MapmyBiome at-home gut microbiome test uses a non-invasive stool sample to examine the bacterial environment in the intestines.
That existing product helps explain one of the testing categories named in the acquisition announcement. It does not establish how the companies will integrate their services or which products will be offered through the combined North American platform.
Conclusion
The Mapmygenome acquisition establishes a completed expansion into North American personal genomics. Further company disclosures would be needed to assess the integration timetable and financial contribution; neither was quantified in the announcement.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
